Isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study: Effect of body weight on pharmacokinetics and clinical outcome Free

Introduction: IRAKLIA is an international, open-label, non-inferiority (NI) trial (NCT05405166) investigating isatuximab (Isa) subcutaneous (SC) vs intravenous (IV) administration, plus pomalidomide-dexamethasone (Pd) and the first Phase 3 multiple myeloma (MM) trial using an on-body injector (OBI). IRAKLIA demonstrated NI in its co-primary endpoints: overall response rate (ORR) and steady state trough concentration (C_trough; Cycle(C) 6 Day(D) 1 predose). IsaOBI offers hands-free administration of flat-dose Isa, a small, hidden, retractable needle to prevent sharps injury and low-pressure delivery. Here, we examine the effect of body weight (BW) on pharmacokinetics (PK) as well as efficacy and safety outcomes with flat-dose IsaOBI vs IV + Pd in IRAKLIA.

Methods: Patients (pts) with relapsed/refractory MM ≥18 years (yr) with ≥1 prior line of therapy (LOT) were randomized 1:1 to IsaOBI (1400mg; n=263) or IV (10mg/kg; n=264 weekly in C1, then every 2 weeks + P (4mg/day, D1–21) + d (40mg [20mg if ≥75yr] weekly) in 4-week cycles. This analysis is run by BW (≤65kg, >65–≤85kg, >85kg) which was a stratification factor, and extreme BW (≤50kg, >50–≤100kg, >100kg).

Results: Number of pts per BW group were: ≤50kg [OBI n=16, IV n=14], ≤65kg [OBI n=84, IV n=85], >65–≤85kg [OBI n=117, IV n=118], >85kg [OBI n=62, IV n=65], and >100kg [OBI n=22, IV n=22]. Baseline (BL) demographic and disease characteristics were generally balanced across BW groups for IsaOBI vs IV, including age (median 66yr) and prior LOT (median 2). However, in the >100kg group, more IsaOBI vs IV pts exhibited poor prognostic characteristics including plasmacytoma, International Staging System Stage II/III disease, beta 2-microglobulin level ≥5.5mg/L, estimated glomerular filtration rate <60mL/min/1.73m² and a lower very good partial response (VGPR) rate as best overall response at last regimen. Flat-dose IsaOBI showed adequate exposure (C2D1 C_trough) for all BW groups, with geometric mean ratios (90% CI) vs IV >1: ≤65kg (1.628 [1.294–2.048]), >65–≤85kg (1.303 [1.089–1.560]) and >85kg (1.006 [0.817–1.239]). IsaOBI ORRs were comparable to IV across BW: ≤65kg, 66% vs 71% (relative risk [RR]: 0.928), >65–≤85kg, 70% vs 70% (RR: 1.009), and >85kg, 81% vs 72% (RR: 1.115). For extreme BW groups, ORRs (95% CI) were similar between IsaOBI and IV for ≤50kg group [56% vs 60%] and for >50–≤100kg [72(66–78)% vs 70(63–76)%] but lower [68% vs 86%] in >100kg group. An exposure-response (E-R) analysis showed the impact of BW on response: IsaOBI pts ≤50kg tended to respond less vs IsaOBI pts >50kg despite correct exposure because they were confounded by BL disease characteristicsincluding a higher proportion of high-risk cytogenetics and plasma cells in the bone marrow vs other BW group pts.

For IsaOBI and IV, Grade (Gr)≥3 treatment-emergent adverse events (TEAEs) and Gr≥3 treatment-related TEAEs decreased with increasing BW. They were similar between arms in ≤65kg group (OBI vs IV, Gr≥3 TEAEs: 87% vs 88%; Gr≥3 treatment-related TEAEs: 73% vs 77%). A similar trend was observed in extreme BW groups along with similar incidences between arms in ≤50kg group. While TE serious AEs (TESAEs) and treatment-related TESAEs decreased with increasing BW for IsaIV, incidence was stable in the IsaOBI arm. OBI arm OBI Gr5 TEAEs were similar between groups and arms, except for higher incidence in ≤65kg group (12% vs 5%) with OBI vs IV that was not reflected in ≤50 or >50–≤100kg groups. Treatment discontinuation rates for all drugs with IsaOBI vs IV were 14% vs 6% (≤65kg), 8% vs 10% (>65–≤85kg), and 2% vs 10% (>85kg). Similar incidence of Gr≥3 laboratory (lab) neutropenia was observed across BW in IsaOBI: 86.9% (≤65kg), 83.5% (>65–≤85kg) and 83.9% (>85kg). Higher rates of Gr≥3 lab neutropenia were observed in ≤50kg group (93.8%, IsaOBI vs 71.4%, IsaIV), which did not translate into higher rates of neutropenic complications (18.8% vs 14.3%). The E-R analysis revealed no relationship between Isa PK exposure and safety for OBI and IV arms.

Conclusions: No notable impact from IsaOBI flat dosing was observed across BW groups. Flat-dose Isa OBI showed consistent safety and efficacy across different BW groups, with differences likely linked to BL disease characteristics according to the E-R analysis. The IsaOBI C2D1 C_trough, a time-independent predictor of efficacy, was similar to, or higher vs IsaIV in each BW group, supportive of a flat dose providing adequate exposure without need for adjustment.